{{Rsnum
|rsid=35592
|Gene=ABCC1
|Chromosome=16
|position=16047966
|Orientation=plus
|GMAF=0.3857
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABCC1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 38.9 | 54.9
| HCB | 24.8 | 40.1 | 35.0
| JPT | 13.3 | 56.6 | 30.1
| YRI | 29.5 | 52.7 | 17.8
| ASW | 29.8 | 45.6 | 24.6
| CHB | 24.8 | 40.1 | 35.0
| CHD | 22.9 | 45.9 | 31.2
| GIH | 1.0 | 30.7 | 68.3
| LWK | 23.6 | 56.4 | 20.0
| MEX | 8.6 | 43.1 | 48.3
| MKK | 13.5 | 53.2 | 33.3
| TSI | 6.9 | 42.2 | 51.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs35592
|Name_s=
|Gene_s=ABCC1
|Feature=
|Evidence=PubMed ID:18256692
|Annotation=SNP influences the efficacy of methotrexate in patients with psoriasis.
|Drugs=methotrexate
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161149202
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs35592
|overall_frequency_n=53
|overall_frequency_d=128
|overall_frequency=0.414062
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=47
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}